Tag Archives: NASDAQ:LOXO

Oppenheimer Remains a Buy on Loxo Oncology (LOXO)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Loxo Oncology (LOXO – Research Report) today and set a price target of $185. The company’s shares opened today at $173.73. Cann wrote: “Loxo’s lower than estimated 3Q18 loss resulted

Analysts Offer Insights on Healthcare Companies: Loxo Oncology (NASDAQ: LOXO) and Amgen Inc (NASDAQ: AMGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Loxo Oncology (NASDAQ:LOXO) and Amgen Inc (NASDAQ:AMGN) with bullish sentiments. Loxo Oncology (LOXO) Citigroup analyst Yigal Nochomovitz maintained a Buy rating on

Loxo Oncology (LOXO) Gets a Buy Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO). The company’s shares closed on Friday at $159.60. According to TipRanks.com, Prasad is a 3-star analyst with an average return of

Loxo Oncology (LOXO) Received its Third Buy in a Row

After Oppenheimer and Stifel Nicolaus gave Loxo Oncology (NASDAQ: LOXO) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Loxo Oncology today. The company’s shares closed

Oppenheimer Maintains a Buy Rating on Loxo Oncology (LOXO)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO) yesterday and set a price target of $202. The company’s shares closed on Friday at $164. Cann noted: “The incidence of TRK fusion cancers has been

Oppenheimer Reaffirms Their Buy Rating on Loxo Oncology (LOXO)

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO), with a price target of $202. The company’s shares closed yesterday at $167.38. Cann commented: “the LIBRETTO data update for ASCO,